跳至主要内容
临床试验/NCT03921775
NCT03921775已完成3 期

A Multicenter, Randomized, Single-blind, Parallel and Control Phase III Trial Evaluating the Efficacy and Safety of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery.

Jiangsu HengRui Medicine Co., Ltd.1 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2019年5月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
330
试验地点
1
主要终点
Percentage(%) of paticipants who experienced successful anesthesia during operation in each group

研究概览

简要总结

The study is being conducted to evaluate the efficacy and safety of remimazolam tosilate compared to propofol for general anesthesia during elective surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Treatment group A

Experimental

IV pumping of remimazolam tosilate at 6mg/kg/h for anesthesia induction and 1mg/kg/h for anesthesia maintenance

干预措施: Remimazolam Tosilate (Drug)

Treatment B

Active Comparator

IV pumping of propofol at 120~150mg/kg/h for anesthesia induction and 3~12mg/kg/h for anesthesia maintenance

干预措施: Propofol (Drug)

结局指标

主要结局

Percentage(%) of paticipants who experienced successful anesthesia during operation in each group

时间窗: Average of 2 hours

次要结局

  • Time from stop of investigational medicinal product to MOAA/S Score=5(Average of 2 hours)
  • Time from start of investigational medicinal product administration to loss of consciousness(Average of 2 hours)
  • Time from stop of investigational medicinal product to Aldrete Score>9(Average of 2 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验